372 related articles for article (PubMed ID: 3135420)
1. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Hardeman SW; Perry A; Soloway MS
J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
[TBL] [Abstract][Full Text] [Related]
2. When does superficial bladder cancer resist intravesical therapy?
Vögeli T; Ackermann R
Semin Urol; 1990 Nov; 8(4):248-53. PubMed ID: 2284531
[No Abstract] [Full Text] [Related]
3. Rationale for intensive intravesical chemotherapy for superficial bladder cancer.
Soloway MS
J Urol; 1980 Apr; 123(4):461-6. PubMed ID: 6767860
[No Abstract] [Full Text] [Related]
4. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
6. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
8. [Prostatic involvement by urothelial carcinoma in patients with bladder cancer and their implications in the clinical practice].
Huguet J
Actas Urol Esp; 2012 Oct; 36(9):545-53. PubMed ID: 22520044
[TBL] [Abstract][Full Text] [Related]
9. Intravesical chemotherapy for superficial bladder cancer.
Koontz WW
Urology; 1984 Apr; 23(4 Suppl):79-81. PubMed ID: 6424298
[No Abstract] [Full Text] [Related]
10. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
11. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
[TBL] [Abstract][Full Text] [Related]
12. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
Baker WC; Russo MA; deVere White RW
Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
[TBL] [Abstract][Full Text] [Related]
13. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
Smith G; Elton RA; Chisholm GD; Newsam JE; Hargreave TB
Br J Urol; 1986 Dec; 58(6):659-63. PubMed ID: 3099881
[TBL] [Abstract][Full Text] [Related]
14. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
Huben RP
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
[TBL] [Abstract][Full Text] [Related]
15. [Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
Lingnau A; Miller K; Steiner U; Jentzmik F; Weikert S; Schostak M
Aktuelle Urol; 2009 Sep; 40(5):307-9. PubMed ID: 19637135
[TBL] [Abstract][Full Text] [Related]
16. A new staging system for transitional cell carcinoma involvement of the prostate and reconfirmation studies of intravesical therapy for superficial bladder cancer.
Hudson MR
J Urol; 1996 Sep; 156(3):972-4. PubMed ID: 8709376
[No Abstract] [Full Text] [Related]
17. Introduction and overview of intravesical therapy for superficial bladder cancer.
Soloway MS
Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
[TBL] [Abstract][Full Text] [Related]
18. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
19. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
20. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
